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Receptor desensitization is a phenomenon in which receptor responsiveness decreases after continued or repeated stimulation with an agonist. After termination of agonist stimulation, desensitization is followed by resensitization, the reinstatement of the ability to respond to ligands (Krupnick and Benovic, 1998) . For G protein-coupled receptors (GPCRs), trafficking of the receptor through various subcellular compartments is an important part of desensitization and resensitization. A model of GPCR desensitization, best characterized for the β 2 -adrenergic receptor, has been developed in which the agonist-activated GPCR is phosphorylated by GPCR kinases (GRKs) or second messenger-dependent kinases such as protein kinase A (Krupnick and Benovic, 1998) . Phosphorylation by GRKs enhances the interaction of the GPCR with additional proteins, termed arrestins. Binding of arrestin causes rapid desensitization of the receptor by inhibiting receptor binding to G proteins, and also targets the receptor to clathrincoated pits for internalization and either degradation or resensitization (Pippig et al., 1995; Tsao et al., 2001) . Arrestin can also act as a scaffolding protein, promoting the stable association of signaling proteins with the receptor (Luttrell et al., 2001 ).
The rate of GPCR resensitization depends on the stability of the receptor:arrestin complex.
Receptors that dissociate from arrestin near the cell membrane (called class A receptors) are rapidly dephosphorylated and recycled, whereas receptors that remain associated with arrestin during internalization (class B receptors) are dephosphorylated and recycled more slowly (Shenoy and Lefkowitz, 2003) . Class A and B receptors can also be differentiated on the basis of their affinities for arrestins, with class A receptors, including the D1 dopamine receptor, having higher affinity for arrestin3 than for arrestin2, whereas class B receptors have similar affinity for arrestin2 and arrestin3 (Oakley et al., 2000) .
This article has not been copyedited and formatted. The final version may differ from this version. Desensitization and internalization of the dopamine D2 receptor have been described in a variety of cell lines and tissue preparations (Ng et al., 1997; Boundy et al., 1995; Barton et al., 1991; Zhang et al., 1994; Sibley and Neve, 1997; Kim et al., 2001; Vickery and von Zastrow, 1999; Kim et al., 2004) . The interaction of arrestins and the dopamine D2 receptor and the contribution of this interaction to receptor internalization have also been investigated, but chiefly in studies using heterologous expression of arrestins, GRKs, and the D2 receptor in non-neuronal cells. Activation of the heterologously expressed dopamine D2 receptor causes GRK-dependent receptor phosphorylation, translocation of GFP-tagged arrestin2 and 3 to the cell membrane, and receptor internalization that is enhanced by overexpression of GRKs or arrestins and prevented by overexpression of a dominant negative mutant of arrestin3 (Kim et al., 2001; Kim et al., 2004) .
We now report that agonist stimulation caused rapid internalization of the D2 receptor heterologously expressed in NS20Y neuroblastoma cells, and that depletion of endogenous arrestins prevented receptor internalization. In NS20Y cells, agonist-induced colocalization of the D2 receptor with both arrestin2 and arrestin3 suggests that the receptor interacts with both forms, as described for class B receptors, an interpretation supported by the direct binding of both forms of arrestin to the receptor second and third cytoplasmic loops and C-terminus. In neurons, however, the endogenous dopamine D2 receptor preferentially interacted with arrestin2, as indicated by selective agonist-induced D2 receptor colocalization with, coimmunoprecipitation with, and translocation of arrestin2.
This article has not been copyedited and formatted. The final version may differ from this version. Chemicon, Temecula, CA), mouse anti-arrestin2 (1/300 dilution, A47520 from Transduction Laboratories, Lexington, KY), mouse anti-arrestin3 (1/250 dilution, sc-13140 from Santa Cruz Biotechnology, Santa Cruz, CA), goat anti-GST (1/500 dilution, 27-4577-01 from Amersham Biosciences, Piscataway, NJ), monoclonal anti-GFP (1/300, Clontech, Palo Alto, CA), and monoclonal anti-GAPDH (1/50,000, MAB374 from Chemicon, Temecula, CA). Secondary antibodies for confocal microscopy were purchased from Molecular Probes (Eugene, OR), and secondary antibodies for immunoblot analysis from Santa Cruz Biotechnology (Santa Cruz, CA).
The blocking reagent I-block was purchased from Tropix (Bedford, MA). Pregnant SpragueDawley rats at gestation day 13 were obtained from Harlan (Indianapolis, IN). µ M IPTG for 3 hr at room temperature. Bacteria were pelleted and washed with phosphate-buffered saline. Pellets were resuspended in lysis buffer (50 mM Tris, 1 mM EDTA, 1 mg/ml lysozyme, pH 8.0) and incubated for 1 hr with gentle rotation at room temperature. The homogenates were clarified by centrifugation, and 600 µl of supernatant, typically ~1 mg, was applied to the MicroSpin GST Purification Module (Amersham Biosciences, Piscataway, NJ) containing Glutathione Sepharose 4B beads, and purified according to manufacturer's instructions. Eluates were separated by SDS-PAGE and the gel was stained with Gel Code Blue (Pierce, Rockford, IL) to determine the correct molecular weight of each fusion protein. In addition, a BCA protein assay was used to determine protein concentrations of the GST fusion proteins.
Generation of GST Fusion
GST Pulldown. For GST pulldown experiments, striata were dissected from Sprague-Dawley rats and homogenized in GST solubilization buffer (50 mM Tris-HCl, pH 7.4, 0.05 mM EDTA, 10 mM CHAPS, and a Complete protease inhibitor tablet/50 ml) with 5 strokes of a glass-Teflon dounce homogenizer. Samples were centrifuged at 38,000 x g for 30 min and the protein concentration in the resulting supernatant was determined using the BCA Protein Assay kit. To obtain purified arrestins, plasmids were expressed in BL21 cells and arrestins purified using heparin-sepharose chromoatography, followed by Q-Sepharose chromatography (Han et al., 2001 ). Glutathione Sepharose 4B beads containing equal amounts of D2-IC3 GST, D2-IC2 GST, D2-CT GST or GST without insert (~1 mg of protein for each), were incubated with 500 µg of striatal brain homogenate overnight at 4 o C with gentle rotation or with 25 ng of purified arrestin2 or arrestin3 at 4 o C for 2 hours. The beads were washed three times with 20 mM TrisHCl, pH 6.9, containing 70 mM NaCl. Samples were eluted with elution buffer (50 mM TrisHCl, 10 mM glutathione, pH 8.0) for 20 min at room temperature with gentle rotation. Bound
This article has not been copyedited and formatted. The final version may differ from this version. proteins were analyzed by immunoblotting with anti-arrestin2 or anti-arrestin3 as described below. In experiments using purified arrestins, the amount of bound arrestin2 or 3 was calculated from a 4-point standard curve generated using background optical density (i.e., no arrestin) and 3 concentrations of arrestin2 or 3 between 0.625 and 2.5 ng. The amount bound to GST alone was subtracted from the total amount bound to each fusion protein to arrive at a value for amount of arrestin2 or 3 specifically bound to D2-IC3, D2-IC2, or D2-CT. (Neve et al., 1991) . After selection for resistance to G418
D2
(600 µg/ml), pooled populations of D2-EGFP-expressing cells were isolated using a BD FACSVantage SE flow cytometer (Becton Dickinson, San Jose, CA) with excitation at 488 nm.
Cells were maintained at 37˚C in a humidified atmosphere with 10% CO 2 in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 5% fetal bovine serum and 5% calf bovine serum, with 300 µg/ml of G418 Sulfate (Calbiochem Co, San Diego, CA Three independent experiments were done for each cell type and arrestin isoform, with an average of 20 cells per experiment analyzed for each time point.
Receptor Sequestration. Sequestration was measured using the intact cell [ 3 H]sulpiride binding assay described by Kim et al. (2001) . D2-EGFP-and D2-expressing NS20Y cells were grown to 80% confluency. Cells were rinsed and preincubated with serum-free minimal essential medium RNA mixtures were added dropwise to the Lipofectamine2000 mixture and incubated at room temperature for 30 min. After the incubation, the total mixture was added to cells in a 6-well tissue culture cluster, for immunoblotting, or a 10 cm plate, for the internalization assay. Some wells received Lipofectamine 2000 only as a negative control. Additional MEM was added to each well or plate 24 hr after the addition of the RNA mixtures. Twenty-four hr later, the siRNA/MEM mixture was replaced by DMEM containing 10% fetal calf serum. Cells were harvested on the third day following transfection for quantification of arrestin and GAPDH immunoreactivity or D2 receptor sequestration as described above.
Neostriatal Neuronal Cultures. The striatal region was dissected from 4 day-old SpragueDawley rats and incubated in MEM containing 20 U/ml papain for 2 hours at 37 o C. The tissue was then triturated using fire-polished Pasteur pipettes in MEM supplemented with 10% fetal bovine serum, 0.45% glucose, 5 pg/ml insulin, 0.5 mM glutamine, 100 U/ml penicillin, and 100 µ g/ml streptomycin. Cells were plated on poly-D-lysine-treated glass coverslips at a density of 75,000 cells per coverslip. Neuronal medium containing 50% MEM, 39% Ham's F12 medium, 10% horse serum, 1% fetal bovine serum, 0.45% glucose, 5 pg/ml insulin, 0.1 mg/ml apotransferrin, 0.5 mM kynurenic acid, and 1 µ g/ml glia-derived neurotrophic factor, was added This article has not been copyedited and formatted. The final version may differ from this version. Cells were grown in a humidified 5% CO 2 incubator at 37 o C and used after 6-8 days in culture.
Arrestin Translocation. Striatal cultures were treated with 7-OH DPAT (10 µM) or vehicle for 20 or 120 min, then rinsed with calcium-and magnesium-free phosphate-buffered saline containing 25 mM EDTA. Cultures were scraped from plates and triturated, after which nuclei were pelleted by centrifugation at 500 x g for 10 min at 4°C. The supernatant was centrifuged at 100,000 x g for 30 minutes at 4°C. The pellets were resuspended in solubilization buffer (25 mM Tris, 150 mM NaCl with 1% CHAPS, pH 7.4), including a Complete protease inhibitor tablet and sonicated for 10 seconds. Protein concentrations were determined using the BCA Protein Assay kit (Pierce, Rockford, IL), and 50 µg of protein/sample was used for quantification of arrestin2 and 3 by immunoblotting.
Immunoblots. Proteins were separated by SDS-PAGE through a 10% polyacrylamide gel and transferred to polyvinyl membranes (Millipore, Bedford, MA). The membranes were blocked overnight with I-block (0.2% with 0.1% Tween 20 in Tris-buffered saline (TBS), pH 7.4) at 4°C, washed twice for 5 min, followed by two 10-min washes with TBS, and incubated with antiarrestin2 or anti-arrestin3 antibody at room temperature for 2 hr or with anti-dopamine D2
receptor antibody overnight at 4°C. The PVDF membranes were again washed twice for 5 min, and twice for 10 min TBS, then incubated with secondary antibody at a dilution of 1:3000 (alkaline-phosphatase conjugated anti-mouse IgG or anti rabbit IgG, from Santa Cruz Biotechnology, Santa Cruz, CA) at room temperature for 1 hr. Membranes immunoblotted with anti-GAPDH were first stripped with 0.2M NaOH for 15 min at room temperature, followed by 2 15-min washes with TBS, then incubated with I-block as described. Stripped blots were then incubated with anti-GAPDH antibody, washed as described, and incubated with alkalineThis article has not been copyedited and formatted. The final version may differ from this version. Cultures were scraped and collected, and CHAPS was added at a final concentration of 1%.
Lysates were incubated on ice for 1 hr, and then centrifuged at 17, 500 x g for 15 min at 4°C.
Protein concentrations of the supernatants were determined using the BCA Protein Assay suggesting a direct interaction of the third loop of the D2 receptor with both isoforms of arrestin (Fig. 1A ). There was little or no specific binding of arrestin2 or 3 to D2-IC2 and D2-CT, as indicated by the lack of arrestin immunoreactivity in eluates from both fusion proteins incubated with striatal homogenates (Fig. 1A) . Similar experiments were carried out with purified arrestin2 and arrestin3 (Fig. 1B) . D2-IC3 bound an average of 1.3 ± 0.3 ng and 1.6 ± 0.4 ng of purified arrestin2 and 3, respectively (N = 4). D2-CT also bound purified arrestin2 (0.5 ± 0. We also used D2-NS20Y cells to confirm that similar results were observed for wildtype D2
and D2-EGFP receptors. Treatment with 7-OH DPAT (10 µM) for 120 min increased the colocalization of the D2 receptor with arrestin2 and 3 from basal levels of 10 + 2% and 9.5 + 3%, respectively, to 46 + 5 % and 55 + 10% after treatment with the D2 receptor agonist (p < 0.001, N = 3). arrestins were depleted by transfection with arrestin2 and arrestin3 siRNAs (Fig. 4B) .
Agonist-induced

Agonist-induced Colocalization of Endogenous D2 Receptor and Arrestin2, but not
Arrestin3, in Neostriatal Neurons. Agonist-induced trafficking of the endogenous dopamine D2 receptor and arrestin2 and 3 in neostriatal cultures was investigated using cells that were treated with 7-OH DPAT, fixed with paraformaldehyde, and immunostained with D2 receptor and arrestin antibodies as described in Materials and Methods. Treatment with 7-OH DPAT (10 µM) increased the colocalization of arrestin2 and the endogenous D2 receptor from 20 + 5% in untreated cells to 46 + 7% after agonist treatment for 2 hr (p < 0.05, N = 3; Fig. 5 ). Shorter durations of treatment had no significant effect on colocalization with arrestin2. In contrast, the colocalization of the endogenous D2 receptor with arrestin3 decreased from 43 + 10% to 13 + 2%, 10 + 4%, and 18 + 6% after 7 OH-DPAT treatment for 5, 60, or 120 min, respectively (Fig.   5 ).
Agonist-induced Translocation of Arrestin2 in Neostriatal Neurons. To confirm that
agonist-induced colocalization of D2 receptor and arrestin2 in neurons represents translocation of the adaptor protein to the membrane, the abundance of arrestin2 and 3 was determined in membranes prepared from neostriatal neurons treated with 7-OH DPAT (10 µM) for 20 or 120 min. The abundance of arrestin2 in the membrane was enhanced by 91 ± 31% (p < 0.05, N = 3) after treatment with agonist for 2 hr but not after 20 min (Fig. 6 ). There was no significant This article has not been copyedited and formatted. The final version may differ from this version. ) and 36 ± 8% (p < 0.05, N=3), respectively (Fig. 7) . There was no significant effect of agonist treatment on the coprecipitation of the dopamine D2 receptor and arrestin3.
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Discussion
The mechanisms of desensitization and resensitization of the dopamine D2 receptor have not been thoroughly elucidated, although studies using heterologously expressed arrestin and/or GRKs in non-neuronal cells suggest an important role for those proteins (Kim et al., 2001; Ito et al., 1999; Kim et al., 2004) . Our aim was to investigate whether the dopamine D2 receptor differentiates between the two isoforms of endogenous non-visual arrestins.
For many GPCRs, the third intracellular loop is the main site of interaction with arrestin (Gelber et al., 1999; DeGraff et al., 2002; Krupnick et al., 1994; Wu et al., 1997; Mukherjee et al., 1999; Kim et al., 2001) , although the first and second intracellular loops and the carboxy terminus also contribute to the binding of arrestin to some GPCRs (Cen et al., 2001; Raman et al., 1999; Bennett et al., 2000; Nakamura et al., 2000; Hüttenrauch et al., 2002) . Using a GST pull-down assay, we determined that the third intracellular loop of the D2 receptor bound both arrestin2 and 3 in neostriatal homogenate and bound similar amounts of purified arrestin2 and 3, suggesting that the third loop of the D2 receptor has no inherent selectivity for either form of arrestin. Both forms of purifed arrestin bound to the C-terminus and the second cytoplasmic loop of the D2 receptor, but less avidly than to D2-IC3, which may account for the lack of specific binding when using neostriatal homogenate as the source of arrestins. The C-terminus bound purified arrestin3 preferentially, but a lesser contribution of this receptor domain to arrestin binding might account for the lack of other evidence for preferential binding of arrestin3.
Arrestin binding is driven both by a conserved "phosphate sensor", involving salt bridges in the polar core of arrestin that are disrupted by the electrostatic interaction of phosphorylated residues in the GPCR with positively charged residues in arrestin, and by a theoretical "GPCR activation sensor" that interacts with residues exposed in the activated GPCR (Gurevich and This article has not been copyedited and formatted. The final version may differ from this version. Gurevich, 2004) . Thus, although binding of arrestin to GPCRs is enhanced by receptor phosphorylation, there are also phosphorylation-independent determinants of binding that are sufficient for binding to occur between isolated GPCR cytoplasmic domains and arrestin (Wu et al., 1997; DeGraff et al., 2002; Cen et al., 2001; Shiina et al., 2000) . Arrestin is presumably binding to sites on the fusion proteins that are occluded in the inactive GPCR and made accessible by receptor activation or, in this case, by removing them from the context of the intact receptor.
To evaluate the effects of D2 receptor stimulation on endogenous arrestins in a cell system, we first used confocal microscopy to quantify their agonist-induced colocalization. In NS20Y cells stably expressing D2-EGFP, colocalization of the receptor with both arrestin2 and 3 was markedly enhanced by agonist treatment for 2 hr, but not by shorter treatments. Although colocalization is not proof of interaction, this is consistent with the well-established observation that agonist-activated GPCRs bind arrestins, and consistent with the binding of both arrestin2 and 3 to D2-IC3, D2-IC2, and D2-CT. Similar results were observed using GFP-tagged arrestins co-expressed with D2 L in CHO cells (Kim et al., 2004) . The apparent nonselectivity of the D2 receptor for the arrestin subtypes is typical of class B receptors such as the neurotensin NT1 and vasopressin V2 receptors (Oakley et al., 2000) .
In neostriatal neurons, in contrast, agonist treatment for 2 hr selectively enhanced the colocalization of the endogenous D2 receptor with endogenous arrestin2, whereas colocalization with arrestin3 was rapidly decreased by 7-OH-DPAT, an efficacious dopamine D2-like receptorselective agonist (Chio et al., 1994) . Selective translocation of arrestin2 in neurons was confirmed by quantifying arrestin immunoreactivity in membranes prepared from agonist-treated neuronal cultures; the abundance of arrestin2, but not arrestin3, was enhanced after treatment for together with the results of the GST pull-down assay, we propose that the D2 receptor can bind both arrestin2 and 3, but that an interaction with arrestin3 is prevented in neostriatal neurons.
One possible mechanism for selective interaction with arrestin2 in neurons is separate compartmentalization of the D2 receptor and arrestin3. Another possibility is that arrestin2 is simply much more abundant in neostriatal tissue , although the ability to pull down similar amounts of arrestin2 and arrestin3 from neostriatal homogenates using D2-IC3-GST suggests that our results cannot be explained in this way. The high basal colocalization of arrestin3 and the D2 receptor in neurons may not reflect an interaction between the proteins, since any stimulus such as constitutive activity of other GPCRs that recruits arrestins to the cell membrane will alter the apparent colocalization of arrestins with all other membrane proteins.
We also evaluated the role of arrestins in D2 receptor internalization in NS20Y cells. These results are similar to prior work demonstrating agonist-induced internalization of the D2 L receptor in CHO, HEK293, and Neuro2A neuroblastoma cells (Itokawa et al., 1996; Vickery and von Zastrow, 1999) , although others have observed little or no internalization in the absence of overexpressed GRK or arrestin (Ito et al., 1999; Kim et al., 2001; Kim et al., 2004) . Suppression of the expression of arrestin2 and 3 by transfection with siRNAs greatly decreased the internalization of the D2 receptor, indicating that D2 receptor internalization requires arrestin.
This is consistent with prior work demonstrating that expression of a dominant negative arrestin mutant inhibits D2 receptor internalization (Kim et al., 2004) .
The time course of the trafficking of endogenous arrestins, however, was much slower than that determined using heterologously expressed arrestins (Shenoy and Lefkowitz, 2003) .
Translocation of endogenous arrestins to the membrane and agonist-induced colocalization of the D2 receptor and arrestins were not significantly increased for at least 60 min, and only coprecipitation of the D2 receptor and arrestin2 was significantly enhanced within 20 min of agonist treatment, when receptor internalization was maximal. According to the prevailing model of GPCR trafficking in which the binding of arrestin to agonist-activated, phosphorylated receptor mediates receptor desensitization and internalization (Krupnick and Benovic, 1998 receptor-induced changes in the distribution of a fraction of endogenous arrestin might be difficult to detect on the background noise of high arrestin concentrations. In the coprecipitation assay, on the other hand, where rapid agonist-induced changes were observed, a high ratio of arrestin to receptor would not affect the signal-to-noise ratio, because the only arrestin being measured is that which is bound to the receptor. Despite the seeming mismatch between the time courses of receptor internalization and some measures of arrestin translocation, the finding that siRNA-induced depletion of endogenous arrestins prevents receptor internalization provides strong support for the hypothesis that arrestin binding to the D2 receptor is required for receptor internalization.
The classification of GPCRs has been investigated chiefly using recombinant GPCR-and arrestin-overexpressing cell lines (Oakley et al., 2000; Shenoy and Lefkowitz, 2003) , and other work suggests that not all rhodopsin-family GPCRs fit neatly within the A or B classification (Mukherjee et al., 2002; Tulipano et al., 2004) . In this study we have determined that although the D2 receptor interacts with endogenous arrestin2 and 3 in NS20Y cells and in vitro, characteristic of a class B receptor, the neostriatal D2 receptor interacts selectively with endogenous arrestin2 upon agonist activation. This article has not been copyedited and formatted. The final version may differ from this version. 
